Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy.
U.O.C. Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Target Oncol. 2018 Oct;13(5):649-655. doi: 10.1007/s11523-018-0588-8.
The CHAARTED and LATITUDE trials demonstrated improved outcomes with docetaxel or abiraterone plus androgen deprivation therapy in metastatic hormone sensitive prostate cancer (mHSPC) using two different prognostic scores.
The aim of our study was to assess the concordance between the two scores and if these retained their prognostic value exclusively in de novo mHSPC.
De novo mHSPC patients referring to our institution were retrospectively stratified according to the CHAARTED and LATITUDE classifications: high volume/high risk (HV/HR), low-volume/low-risk (LV/LR), and HVorHR (HV/LR and LV/HR). The Kaplan-Meier method and Cox proportional-hazard models were used to estimate hazard ratios for overall survival.
The study population included 106 patients. Concordance between the CHAARTED and LATITUDE classifications was observed in 86.8% of cases (65.1% HV/HR, 21.7% LV/LR), while 13.2% of patients fulfill the criteria of only one of the two classifications (HVorHR). When analyzed independently, the CHAARTED and LATITUDE classifications maintained their prognostic value (mOS 28.2 months in HV versus 60.9 months in LV, p = 0.006; 28.2 months in HR versus 40.6 months in LR, p = 0.017). The LR/LV population showed significantly longer mOS compared to the HR/HV group (72.6 months versus 26.3 months; p = 0.005), and to HVorHR patients (35.1 months; p = 0.003). No difference in OS was observed between HV/HR and HVorHR patients. ECOG PS ≥ 1 and patient age improved the prognostic value of the two classifications with multivariate analysis.
Our study showed a lack of complete concordance between the CHAARTED and LATITUDE classifications. The analysis confirmed the role of these prognostic scores to stratify de novo mHSPC patients in clinical practice.
CHAARTED 和 LATITUDE 试验表明，在转移性激素敏感前列腺癌（mHSPC）中，使用两种不同的预后评分，多西他赛或阿比特龙联合雄激素剥夺疗法可改善结局。
我们研究的目的是评估这两种评分之间的一致性，以及它们是否仅在初发 mHSPC 中保留其预后价值。
回顾性地根据 CHAARTED 和 LATITUDE 分类将就诊于我院的初发 mHSPC 患者分层：高容量/高风险（HV/HR）、低容量/低风险（LV/LR）和 HV 或 HR（HV/LR 和 LV/HR）。使用 Kaplan-Meier 方法和 Cox 比例风险模型估计总生存期的风险比。
研究人群包括 106 例患者。CHAARTED 和 LATITUDE 分类之间的一致性在 86.8%的病例中观察到（65.1%HV/HR，21.7%LV/LR），而 13.2%的患者符合两种分类之一的标准（HV 或 HR）。当单独分析时，CHAARTED 和 LATITUDE 分类保持其预后价值（在 HV 中 mOS 为 28.2 个月，在 LV 中为 60.9 个月，p=0.006；在 HR 中 mOS 为 28.2 个月，在 LR 中为 40.6 个月，p=0.017）。LR/LV 人群的 mOS 明显长于 HR/HV 组（72.6 个月比 26.3 个月；p=0.005），也长于 HV 或 HR 患者（35.1 个月；p=0.003）。在 OS 方面，HV/HR 和 HV 或 HR 患者之间没有差异。ECOG PS≥1 和患者年龄通过多变量分析改善了两种分类的预后价值。
我们的研究表明，CHAARTED 和 LATITUDE 分类之间缺乏完全一致性。该分析证实了这些预后评分在初发 mHSPC 患者的临床实践中的作用。
